Simsen Diagnostics AB Announces Collaboration with Sahlgrenska University Hospital for Pancreatic Cancer Study

Simsen Diagnostics AB, a leader in cancer monitoring, is pleased to announce a collaboration with Professor Peter Naredi and his research group at Sahlgrenska University Hospital. This partnership focuses on enhancing the detection and monitoring of pancreatic cancer, using Simsen Diagnostics’ technology, Simsen Personal.

Pancreatic cancer is one of the most deadly cancers, often diagnosed at an advanced stage. Early detection is challenging due to the limited sensitivity of current diagnostic tools. To overcome these obstacles, Naredi and his research group aim to investigate Simsen Diagnostics’ solution, Simsen Personal—a highly sensitive method for detecting and monitoring cancer DNA from blood samples. The collaboration seeks to utilize Simsen Personal aiming to identify the disease in its early stages.

Professor Peter Naredi, leading the research group at the Department of Surgery, Sahlgrenska University Hospital, stresses the importance of early detection. “The only chance for a cure is to detect tumors in the early stages so that they can be surgically removed. Our collaboration with Simsen Diagnostics offers a novel approach to achieving this goal.” said Naredi. Simsen Personal is designed to monitor patient-specific mutations, improving the sensitivity of cancer detection.

Naredi further explains: “We are utilizing Simsen Diagnostics’ ultrasensitive technology to identify specific traces of cancer in the blood of each individual patient. If we can identify such biomarkers in the blood, it may provide a way to detect cancer or precancerous stages early in at-risk patients.”

About Simsen Diagnostics

Simsen Diagnostics is a biotech startup focusing on transforming cancer monitoring. Specializing in designing patient-specific tests, Simsen Personal, the flagship solution, is based on ultrasensitive technology capable of detecting cancer years before standard-of-care tools. Founded in 2020 as a research spin-out from Sahlgrenska Academy, Simsen Diagnostics has experienced steady growth, gaining recognition from the pharmaceutical industry. Situated in BioventureHub at AstraZeneca Gothenburg, the company is at the forefront of providing innovative solutions in cancer monitoring.

Pontus Rehn

Chief Executive Officer (CEO)

Pontus Rehn has over 20 years of experience in commercial leadership roles in the medical device and IVD industries, including global and regional positions like VP Market Development, Chief Commercial Officer, and Director of Commercial Strategy. 

Lina Said

Laboratory and Quality Manager

Lina Said, a licensed Biomedical Scientist, brings 18 years of experience from Sahlgrenska University Hospital to her role as the Lab and Quality Manager at Simsen Diagnostics. Her primary focus is ensuring quality assurance and fostering an optimal work environment for the lab. 

My Vu

Lead Laboratory Technician

My Vu is currently doing a master’s degree in biotechnology and demonstrates expertise in laboratory procedures. Her previous experience includes analyzing COVID samples and conducting her bachelor’s thesis at Fraunhofer. My is analyzing all the samples that comes to the lab.  

Stefan Filges

Chief Technology Officer (CTO)

Stefan Filges, an accomplished bioinformatician with a Ph.D. in ultrasensitive sequencing, became part of Simsen Diagnostics in 2022. He played a crucial role as a co-author in the original publication of SiMSen-Seq, which was published in Nature Protocols. 

Camilla Hietanen

Head of Sales and Marketing

Camilla Hietanen holds an M.Sc. in Business Development from the Chalmers School of Entrepreneurship. Her academic background encompasses studies in Sports & Nutrition, and she brings prior experience from various Start-ups. Within Simsen Diagnostics, her primary focus lies in Sales and Marketing. 

Almost there

Sign up on our maillist to gain access to your article. You can at any time unsubscribe from the list.